SILO News & Events

Silo Pharma announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury and associated neuropsychiatric conditions. Silo has filed a provisional patent application with the United States Patent and Trademark Office titled "Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine." The invention applies to the use of ibogaine and related compounds for the treatment of TBI, post-traumatic stress disorder and associated conditions.

Silo Pharma announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents. "We expect that Silo's diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy," said Eric Weisblum, CEO.